Quercetin supplementation does not alter antioxidant status in humans

Abstract

This study measured the influence of ingesting quercetin on plasma measures for oxidative stress and antioxidant capacity. Male and female subjects (n = 1002) varying in age (18–85 years) and body mass index (BMI) (16.7–52.7 kg/m²) were studied. Subjects were randomized to one of three groups using double-blinded methods: placebo, 500 mg or 1000 mg quercetin/day with 125 mg or 250 mg vitamin C/day, respectively. Pre- and post-study fasting blood samples show that plasma quercetin increased in a dose-responsive manner. The pattern of change in plasma F₂-isoprostanes, oxidized low density lipoprotein, reduced glutathione, ferric reducing ability of plasma (FRAP) and oxygen radical absorbance capacity (ORAC) did not differ between supplementation groups or after adjustment for gender, age, BMI and disease status. In summary, quercetin supplementation over 12 weeks in doses of 500 mg or 1000 mg/day significantly increased plasma quercetin levels, but had no influence on several measures of oxidative stress and antioxidant capacity.     

Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study

Electronegative LDL, a charge-modified LDL (cm-LDL) subfraction that is more negatively charged than normal LDL, has been shown to be inflammatory. We previously showed that pravastatin and simvastatin reduced the electronegative LDL subfraction, fast-migrating LDL (fLDL), as analyzed by capillary isotachophoresis (cITP). The present study examined the effects of rosuvastatin on the more electronegative LDL subfraction, very-fast-migrating LDL (vfLDL), and small, dense charge-modified LDL (sd-cm-LDL) subfractions. Patients with hypercholesterolemia or those who were being treated with statins (n = 81) were treated with or switched to 2.5 mg/d rosuvastatin for 3 months. Rosuvastatin treatment effectively reduced cITP cm-LDL subfractions of LDL (vfLDL and fLDL) or sdLDL (sd-vfLDL and sd-fLDL), which were closely related to each other but were different from the normal subfraction of LDL [slow-migrating LDL (sLDL)] or sdLDL (sd-sLDL) in their relation to the levels of remnant-like particle cholesterol (RLP-C), apolipoprotein (apo) C-II, and apoE. The percent changes in cm-LDL or sd-cm-LDL caused by rosuvastatin were correlated with those in the particle concentrations of LDL or sdLDL measured as LDL-apoB or sdLDL-apoB and the levels of HDL-C, RLP-C, apoC-II, and apoE. In conclusion, rosuvastatin effectively reduced both the vfLDL subfraction and sd-cm-LDL subfractions as analyzed by cITP.     

乳腺癌患者改良根治术后生活质量调查及复发转移的影响因素分析

目的:调查乳腺癌患者改良根治术后生活质量,并对其复发转移的影响因素进行分析。方法:选取2012年6月～2014年6月期间于我院行改良根治术的乳腺癌患者197例,于术后3个月、术后6个月、术后12个月采用乳腺癌患者生命质量测定量表(FACT-B)评价患者生活质量。采用我院自制的调查问卷统计患者基本治疗情况,分析乳腺癌改良根治术后复发转移的影响因素。结果:本研究中,共发放197份问卷调查,回收195份,回收率为98.98%(195/197)。其中195例患者中有73例发生复发转移(复发转移组),122例未发生复发转移(未复发转移组)。195例乳腺癌患者术后3个月、术后6个月、术后12个月社会/家庭状况、生理状况、功能状况、情感状况、附加关注条目、总体生活质量等项目评分呈递增趋势(P0.05)。多因素Logistic回归分析显示,病理类型为浸润性非特殊性癌、肿瘤大小≥2 cm、临床分期为Ⅲ期、激素受体为ER及PR均阴性均是乳腺癌改良根治术后复发转移的独立危险因素(P0.05),而采用放化疗、联合化疗方案、内分泌治疗以及p53蛋白阳性表达是乳腺癌改良根治术后复发转移的独立保护因素(P0.05)。结论:乳腺癌患者行改良根治术后生活质量呈动态变化,其术后复发转移影响因素为病理类型、临床分期、肿瘤大小、激素受体、化疗方案、p53蛋白、内分泌治疗及放化疗。     

Natural,modified DNA bases

The four canonical bases that make up genomic DNA are subject to a variety of chemical modifications in living systems. Recent years have witnessed the discovery of various new modified bases and of the enzymes responsible for their processing. Here, we review the range of DNA base modifications currently known and recent advances in chemical methodology that have driven progress in this field, in particular regarding their detection and sequencing. Elucidating the cellular functions of modifications remains an ongoing challenge; we discuss recent contributions to this area before exploring their relevance in medicine.     

改良乳腺癌根治术后切口感染的病原学特征、影响因素及其凝血纤溶功能研究

摘要 目的：探讨改良乳腺癌根治术后切口感染的病原学特征、影响因素及其对凝血纤溶功能的影响。方法：选取我院于2016年6月~2020年9月期间收治的390例行改良乳腺癌根治术的乳腺癌患者,分析改良乳腺癌根治术后切口感染的病原学特征、影响因素及术后切口感染对凝血纤溶功能的影响。结果：390例行改良乳腺癌根治术的乳腺癌患者,术后发生切口感染28例,术后切口感染率为7.18%（28/390）,将未发生术后切口感染的患者纳为未感染组（n=362）,发生的纳为感染组（n=28）。28例发生感染的患者共分离培养病原菌36株,其中革兰阳性菌14株,占比38.89%（14/36）,以金黄色葡萄球菌、粪肠球菌为主。革兰阴性菌21株,占比58.33%（21/36）,以大肠埃希菌、铜绿假单胞菌为主。改良根治术后乳腺癌患者切口感染的影响因素包括手术时间、术后住院时间、合并基础疾病、引流时间、年龄、白蛋白（P<0.05）。多因素Logistic回归分析发现：合并基础疾病、年龄≥60岁、白蛋白＜35 g/L、手术时间≥120 min均是改良乳腺癌根治术后切口感染的影响因素（P＜0.05）。两组术后30 d凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）升高,且未感染组高于感染组（P<0.05）,纤维蛋白原（FIB）降低,且未感染组低于感染组（P<0.05）。结论：改良乳腺癌根治术后切口感染较为常见,致病菌以革兰阴性菌为主,年龄、合并基础疾病、白蛋白、手术时间均是其影响因素,同时术后切口感染的发生可影响凝血纤溶功能的恢复,临床医生应积极采取措施预防术后切口感染的发生,从而保证手术治疗效果。     

Modified Fuzzy Q Learning Based Classifier for Pneumonia and Tuberculosis

This work proposes reinforcement learning for correctly identifying pneumonia and tuberculosis (TB) using a repository of X ray images. To our knowledge, this is a first attempt at employing reinforcement learning for pneumonia and TB classification. In particular, modified fuzzy Q learning (MFQL) algorithm in conjunction with wavelet based pre-processing has been used to build a classifier for identifying pneumonia and tuberculosis's severity. Proposed classifier is a self-learning one and uses pneumonia dataset (no pneumonia, mild pneumonia and severe pneumonia) and tuberculosis dataset (TB present, TB absent) samples to classify X ray images of subjects. Results indicate that MFQL based approach achieves high accuracy and fares much better over contemporary Support Vector Machine (SVM) and k-Nearest Neighbor (KNN) classifiers. Proposed classifier can be a useful tool for pneumonia and tuberculosis diagnosis in a practical setting.     

Forthcoming Meetings 1993

The purpose of this review is to bring together the different approaches for studying the oxidation of low density lipoproteins and try to identify some critical factors which will permit greater comparability between laboratories. These issues are discussed both in terms of the variety of exogenous mediators of oxidation applied (transition metal ions, haem proteins, azo initiators, peroxynitrite, cells etc.) and their raisons d'etre, as well as the methodologies (formation of conjugated dienes, hydroperoxides, decomposition products of lipid peroxidation, altered surface charge, macrophage uptake) applicable to the different stages of the oxidation and the factors underlying their accurate execution and interpretation.     

Effect of consumption of phenols from olives and extra virgin olive oil on LDL oxidizability in healthy humans

A high intake of olive oil has been proposed as an explanation for the low incidence of coronary heart disease in Mediterranean countries, but it is unclear whether olive oil offers specific benefits beyond a low content of saturated fat. Some types of extra virgin olive oil are rich in non-polar phenols, which might be taken up by plasma LDL particles and protect these from becoming atherogenic by oxidative modification. In a pilot study we found that consumption of 47 g fortified olive oil containing 31 mg phenols significantly increased the lag time of LDL oxidation from 112 ± 5 min before to 130 ± 7 min 2h after the meal. However, this study was not controlled, and in the current study we therefore investigated whether olive oil phenols increase the lag time of LDL oxidation in postprandial samples when compared with a control group.

Twelve healthy men and women consumed four different olive oil supplements with a meal on four separate occasions: one similar to the supplement in the pilot study (positive control); one containing mainly non-polar olive oil phenols; one containing mainly polar olive oil phenols; and one without phenols (placebo). Lag time significantly increased 2 h after the meals with the positive control (8 ± 2 min), the polar phenols (8 ± 2 min), and the placebo (8 ± 2 min), but not after the non-polar phenols (-0.4 ± 3 min). Increases were not statistically different between supplements.

These results indicate that the lag time of LDL-oxidation is increased after consumption of a meal. This increase is probably due to non-specific meal or time effects and not to phenols from olives or olive oil. Furthermore, these findings stress the need for adequate controlled studies to avoid misinterpretations of the data.     

Investigation of Lipid Peroxidation in Human Low Density Lipoprotein

Human plasma low density lipoprotein (LDL) exposed to oxygen saturated buffer becomes depleted of alpha-tocopherol within 3 to 6 hours. Thereafter, lipid peroxidation commences as evidenced by the loss of 18:2 (67nmol/mg LDL) and 20:4 (12nmol/mg LDL) and the concomitant formation of 4-hydroxy-nonenal (0.28 nmol/mg LDL) and fluorescent compounds. The major fluorophor in apo B of oxidized LDL has an excitation maximum at 355 nm and an emission maximum at 430 nm. A fluorophor with the same spectral properties is produced in apo B, if LDL is incubated with 4-hydroxynonenal, whereas malonal-dehyde gives a fluorophor with excitation and emission maxima at 400/470nm. Three-dimensional fluorescence spcetroscopy proved to be an useful tool in analysing the complex fluorescence of apo B.     

Calcium Antagonists Prevent Monocyte and Endothelial Cell-Induced Modification of Low Density Lipoproteins

Low density lipoprotein (LDL) incubated in the presence of the calcium antagonists verapamil, nifedipine and flunarizine were more resistant than control LDL to human monocyte- or endothelial cell-induced modification, as assessed by electrophoretic mobility in agarose gel, thiobarbituric acid reactive substance content, and degradation by J774 macrophages. The efficiency of the drugs was: flunarizine > nifedipine > veraparml. Moreover, a 24 h preculture with calcium antagonists significantly impaired the ability of cells to modify LDL in the absence of the drugs. All the studied drugs also inhibited copper-induced autooxidation of LDL. None of the studied calcium antagonists, at concentrations up to 10^-4 M, significantly reacted with free radicals as assessed by the l,1-diphenyl-2-picrylhydrazyl test. It is suggested that such a protective effect of calcium antagonists against LDL peroxidation could play a role in the previously reported antiatherogenic effect of these drugs.